Cerenome (CNSY) Q3 2026 Earnings Call Transcript

Cerenome (CNSY) reported Q3 2026 earnings, highlighting progress in diagnostics and therapeutics. CNSide Diagnostics is on track for 1,250 annualized tests and exceeded 150M covered lives. REYOBIQ trials are advancing, with Phase II enrollment completed for ReSPECT-GBM and interim data presented for ReSPECT-LM. The company aims for mid-2027 top-line data and FDA alignment for next steps.

Original reporting
Published Nov 16, 2026, 8:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 8:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cerenome (CNSY) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$CNSYBullishMed
01

Why it matters

The disclosed trial milestones represent the first public data on enrollment completion and interim safety, which are key value drivers for the company.

02

Market read

First‑time trial progress news could move CNSY shares; broader biotech sector may benefit.

03

What to watch

Potential regulatory delays or manufacturing scale‑up challenges could temper upside.

Relevance 8/10Novelty 8/10Timing: post‑earnings call today

Background

Cerenome's Q3 2026 earnings call focused on clinical trial updates for its lead radiopharmaceutical REYOBIQ.

Company-level read

Ticker impact

$CNSYBullishHigh confidence
Context

Cerenome disclosed closure of Phase II enrollment for its REYOBIQ GBM trial and presented interim Phase II data for the ReSPECT-LM trial at the Society of Neuro-Oncology meeting.

Expected impact

likely upward pressure as investors price in favorable trial milestones.

Evidence & confidence

First disclosure of trial enrollment completion and interim safety results for a radiopharmaceutical targeting CNS cancers, a material catalyst for a biotech.

Market effects

strengthens outlook for CNS‑targeted radiopharmaceuticals and may boost peer biotech sentiment.

U.S. biotech sector could see modest gains.

limited to specialty oncology investors.

Counterpoint

Trial data may be early; investors should watch for later efficacy readouts before committing.

Key entities

  • Cerenome

    Biotech developing REYOBIQ for CNS cancers.

  • REYOBIQ

    Liposomal targeted radiopharmaceutical in Phase II trials.

Related articles

$CNSYMedAI 8/10

Cerenome Shares Interim REYOBIQ Data At SNO Meeting; Phase 2 Study Targeted For 2027

Cerenome (CNSY) presented interim Phase 1 data for REYOBIQ at the SNO meeting, showing no dose-limiting toxicities in 10 patients. Imaging confirmed consistent radiation delivery, and no LM progression was seen in evaluable patients at 3 and 6 months. REYOBIQ was generally well-tolerated. The company plans a Phase 2 study in 2027, subject to progress and regulatory alignment.

$CNSYMedAI 8/10

Cerenome Reports Interim REYOBIQ Data: No Dose-Limiting Toxicities in First 10 Patients

Cerenome reported interim data from the ReSPECT-LM study, showing no dose-limiting toxicities in the first 10 patients treated with REYOBIQ. One patient received three doses totaling 79.2 mCi, with consistent radiation delivery. No leptomeningeal (LM) progression was observed at three or six months, with one case at nine months. Cerenome plans a Phase 2 study in 2027, pending regulatory alignment.

$CNSYMedAI 8/10

Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting

CERENOME, INC. (CNSY) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Cerenome Reports Interim ReSPECT-LM Data Supporting Repeat Dosing of REYOBIQ ™ in Leptomeningeal Metastases at the 2026 SNO Annual Meeting No dose-limiting toxicities in the first 10 patients; consistent and reliable dosing of a targeted radiopharmaceutical; early di